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TNFa has recently emerged as a regulator link-
ing inflammation to cancer pathogenesis, but
the detailed cellular and molecular mecha-
nisms underlying this link remain to be eluci-
dated. The tuberous sclerosis 1 (TSC1)/TSC2
tumor suppressor complex serves as a repres-
sor of the mTOR pathway, and disruption of
TSC1/TSC2 complex function may contribute
to tumorigenesis. Here we show that IKKb,
a major downstream kinase in the TNFa signal-
ing pathway, physically interacts with and
phosphorylates TSC1 at Ser487 and Ser511,
resulting in suppression of TSC1. The IKKb-
mediatedTSC1suppression activates themTOR
pathway, enhances angiogenesis, and results
in tumor development. We further find that
expression of activated IKKb is associated
with TSC1 Ser511 phosphorylation and VEGF
production in multiple tumor types and corre-
lates with poor clinical outcome of breast
cancer patients. Our findings identify a path-
way that is critical for inflammation-mediated
tumor angiogenesis and may provide a target
for clinical intervention in human cancer.
INTRODUCTION
The microenvironment around tumors comprises several
distinct types of cells, including fibroblasts, endothelial440 Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc.cells, and inflammatory cells. The identification of inflam-
matory cells in human tumors, first reported by Rudolf
Virchow in 1863, led to the concept, nowwidely accepted,
that the inflammatory cells in the tumor microenvironment
play a critical role in promoting tumor progression, inva-
sion, and angiogenesis (Balkwill and Mantovani, 2001).
Among the factors secreted by tumor-associated-
inflammatory cells, TNFa is a primary proinflammatory
cytokine and is considered to be a potential mediator
involved in several human diseases, including cancers.
Recently, the TNFa/IKKb signaling pathway has been sug-
gested to link inflammation to cancer pathogenesis. It has
been speculated that evasion of apoptosis (Greten et al.,
2004) and insensitivity to antigrowth signals (Hu et al.,
2004) contribute to TNFa-mediated tumor progression;
however, these characteristics are not sufficient for
cancer development—other factors, e.g., sustained an-
giogenesis, are also required (Hanahan and Weinberg,
2000). Although accumulating evidence suggests that
angiogenesis plays a role in inflammation-mediated
tumorigenesis, the underlying mechanism remains to be
further investigated.
Tuberous sclerosis (TSC) is an autosomal-dominant
disease characterized by tumors, which can grow in any
organ of the body, and by numerous abnormal blood ves-
sels around tumors. Two tumor suppressor genes, TSC1
and TSC2, are associated with the development of TSC,
and mutations in either gene are responsible for both the
familial and sporadic forms of TSC (Young and Povey,
1998). TSC1 stabilizes TSC2 through binding with it,
thereby preventing TSC2 from ubiquitination and degra-
dation (Benvenuto et al., 2000). TSC2 acts as a GTPase-
activating protein to regulate RHEB function through
converting RHEB from an active GTP-bound form to an in-
active GDP-bound form (Garami et al., 2003; Inoki et al.,
2003). GTP-bound RHEB is known to activate mTOR,
whereas GDP-bound RHEB loses its ability to activate
mTOR, suggesting that the TSC1/TSC2 complex can
downregulate the mTOR pathway through suppressing
RHEB function.
Upregulation of the TSC/mTOR signaling pathway has
been implicated in the development of cancers. Activation
of S6K1 and inactivation of 4EBP1 through phosphoryla-
tion bymTOR lead to increased protein synthesis, cell pro-
liferation, and VEGF secretion and ultimately to tumori-
genesis (Inoki et al., 2005). Activation of mTOR causes
upregulation of VEGF through increases of both transcrip-
tion (Brugarolas et al., 2003) and translation (Chung et al.,
2002; Klos et al., 2006). Indeed, both Tsc1 null and Tsc2
null MEFs have increased VEGF production, an effect
that is dependent on mTOR activation (El-Hashemite
et al., 2003). In addition, patients with TSC develop renal
acute myelogenous leukemia and skin angiofibromas
that are characterized by numerous abnormal blood
vessels (Young and Povey, 1998), and Tsc1- and Tsc2-
heterozygous mice develop liver hemangiomas asso-
ciated with extensive abnormal vasculization (Kwiatkow-
ski et al., 2002; Onda et al., 1999), suggesting that the
TSC/mTOR signaling pathway plays a role in regulating
angiogenesis.
In this study, we attempted to determine whether angio-
genesis plays a role in TNFa-mediated tumorigenesis. Un-
expectedly, we discovered a previously unrecognized role
of IKKb: IKKb upregulates mTOR activity through inactiva-
tion of TSC1. We concluded that dysregulation of the
TSC/mTOR signaling pathway by IKKb significantly con-
tributes to inflammation-mediated cancer pathogenesis.
RESULTS
TNFa Activates the mTOR Pathway
TNFa is able to induce mTOR activation through the AKT
pathway in certain cell types (Ozes et al., 2001). In an at-
tempt to understand the molecular mechanism for
TNFa-induced mTOR activation by examining the phos-
phorylation status of S6K1 at T389 [pS6K1(T389)] and
4EBP1 at S65 [p4EBP1(S65)], two well-known mTOR
phosphorylation sites, we unexpectedly found that TNFa
substantially induced pS6K1(T389) and p4EBP1(S65)
within 5-10 min but caused virtually no activation of AKT
within 20 min in breast cancer cell lines MCF-7 and
MDA-MB-453 (Figure 1A). In vitro kinase assays further
supported that mTOR and S6K1, but not AKT, were acti-
vated by TNFa stimulation (Figure 1B and Figure S1A in
the Supplemental Data available with this article online).
Since ERK and p38 also induce mTOR activation through
AKT-independent pathways in human fibroblasts (Li et al.,
2003; Ma et al., 2005), we examined whether ERK and p38
play roles in TNFa-induced mTOR activation. There was
no significant ERK or p38 activation by TNFa within
30 min (Figures S1B and S1C) and depletion of AKT1/2/3,ERK1/2, and p38 by siRNA did not block TNFa-induced
mTOR activation (Figures S2A, S2B, and S2C). Further-
more, inhibition of TNFa-induced pS6K1(T389) by mTOR
siRNA supported the notion that TNFa-induced
pS6K1(T389) requires mTOR (Figure 1C). Taken together,
these results suggested that there may be an unknown
signaling cascade—distinct from the AKT, ERK, and
p38-mediated signaling pathways—by which TNFa acti-
vates mTOR in human epithelial breast cancers. Because
activation of the mTOR signaling pathway by TNFa oc-
curred within 10 min, it was unlikely that mTOR activation
was due to transcriptional effects of NF-kB. As expected,
suppression of nuclear translocation of NF-kBby the dom-
inant-negative phosphorylation mutant IkBaM did not
block TNFa-induced mTOR activation (Figure 1D), and
transfection of NF-kB p65 did not upregulate mTOR activ-
ity (Figure 1E). In summary, these results suggested that
TNFa stimulates mTOR signaling by a novel mechanism.
IKKb Activates the mTOR Pathway
Since IKKb is the major downstream kinase in the TNFa
signaling pathway, we asked whether IKKb plays a role
in TNFa-induced mTOR activation. The pS6K1(T389)
levels in multiple MCF-7 and MDA-MB-453 IKKb stable
transfectants were higher than those in the vector control
or kinase-dead IKKb mutant (nIKKb) stable transfectants
(Figure 2A). Similar results were obtained with transient
expression (Figure 2B). This regulation was present not
only in cancer cells but also in mammary epithelial cells
derived from normal tissues (MCF-10A and HBL-100; Fig-
ures 2C and 2D), suggesting that TNFa- and IKKb-induced
mTOR activation is a general phenomenon. Furthermore,
the pS6K1(T389) levels were lower in Ikkb-deficient MEFs
than in wild-type MEFs but were restored after IKKb, but
not IKKa, was added back (Figure 2E, left panel). Consis-
tently, only IKKb, but not IKKa, increased pS6K1(T389)
levels in Ikka-deficient MEFs (Figure 2E, right panel).
siRNA-mediated knockdown of IKKb caused a decrease
in pS6K1(T389) (Figure 2F) and abrogated TNFa-induced
pS6K1(T389) (Figure 2G, left panel). Since IKKg plays an
essential role in IKKb activation, we examined whether
IKKg is required for TNFa-mediated mTOR activation. In-
deed, siRNA-mediated knockdown of IKKg significantly
inhibited TNFa-induced mTOR activation (Figure 2G, right
panel). The mTOR inhibitor rapamycin completely dimin-
ished pS6K1(T389) induced by TNFa and IKKb but had
much less effect on the level of pS6K1(T389) induced by
a rapamycin-insensitive mTOR (S2035T) (Brown et al.,
1995) (Figures 2H and 2I). Transfection of nIKKb and
pretreatment with two structurally unrelated IKKb
inhibitors—BAY 11-7082 and parthenolide—abrogated
TNFa-induced pS6K1(T389) (Figures 2H and 2J), further
supporting the crucial role of IKKb in TNFa-induced
mTOR activation.
Since the proinflammatory cytokine IL-1b and LPS func-
tion as IKKb activators, we also examined whether mTOR
activity is upregulated in response to IL-1b and LPS. As
expected, IL-1b- and LPS-induced mTOR activationsCell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc. 441
Figure 1. TNFa Activates the mTOR Pathway
(A) TNFa induced pS6K1(T389) and p4EBP1(S65) in MCF-7 and MDA-MB-453. Cells were serum-starved overnight and then treated with 20 ng/ml
TNFa in a time-course study.
(B) TNFa increased the kinase activities of S6K1 and mTOR. MCF-7 cells were serum-starved overnight and then treated with 20 ng/ml TNFa for
30min. Endogenous S6K1 andmTORwere immunoprecipitated and incubatedwith GST-S6 andGST-4EBP1 fusion proteins for 30min, respectively.
(C) Knockdown of mTOR by mTOR siRNA downregulated pS6K1(T389) in MCF-7 cells. MCF-7 cells were cotransfected with HA-tagged S6K1 and
mTOR siRNA, serum-starved overnight, and then treated with 20 ng/ml TNFa for 30 min.
(D) Inhibition of NF-kB by IkBaM did not impair TNFa-induced mTOR activation.
(E) NF-kB p65 did not increase pS6K1(T389).were similar to TNFa-induced mTOR activation in their
responsive cells MCF-7 and mouse RAW264.7 macro-
phages, respectively (Figure 3A). Furthermore, siRNA-
mediated knockdown of IKKb abrogated IL-1b- and
LPS-induced pS6K1(T389) (Figures 3B and 3C). These
observations supported the notion that mTOR activity
may be regulated by several different inflammatory cyto-
kines via IKKb.
The mTOR pathway integrates signals from mitogenic
growth factors, nutrients, stress, and cellular energy level
to promote protein synthesis and cell growth (Fingar and
Blenis, 2004; Hay and Sonenberg, 2004). Many signaling
molecules, including IGF1, EGF, WNT3a (Inoki et al.,
2006), glucose, and amino acids, can activate the mTOR
pathway. To determine how the degree of mTOR activa-442 Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc.tion in response to TNFa compared with the degree of
mTOR activation in response to other agonists, we exam-
ined pS6K1(T389) induction by TNFa, IGF1, EGF, WNT3a,
glucose, and amino acids, and found that TNFa-mediated
mTOR activation was similar to mTOR activation by IGF1,
EGF, WNT3a, and glucose under physiological conditions
(Figure 3D). To further addresswhether IKKb is required for
other agonists-mediated mTOR activation, we examined
these agonists-mediated mTOR activation in both Ikkb-
deficient MEFs and IKKb-knockdown MCF-7 cells. Nei-
ther Ikkb knockout nor IKKb knockdown had significant
effects on IGF1-, EGF-, or WNT3a-induced pS6K1(T389)
(Figures 3E and 3F), indicating that IKKb is specifically
required for inflammatory cytokines—but not mitogens—
induced mTOR activation.
Figure 2. IKKb is Required for TNFa-Mediated mTOR Activation
(A) Higher levels of pS6K1(T389) were observed in IKKb (b) than in vector control (V) or nIKKb (nb) stable transfectants.
(B) Transient transfection of IKKb increased pS6K1(T389) in MCF-7 cells.
(C) TNFa induced pS6K1(T389) and p4EBP1(S65) in MCF-10A and HBL-100 cells. Asterisks are as follows: *, short exposure; **, long exposure.
(D) Transient transfection of IKKb upregulated pS6K1(T389) in HBL-100 cells.
(E) pS6K1(T389) was lower in Ikkb/ MEFs than in wild-type (Wt) MEFs and was restored by re-introduction of IKKb but not IKKa.
(F) Knockdown of IKKb by IKKb siRNA downregulated pS6K1(T389) in MDA-MB-453 cells.
(G) siRNA-mediated knockdown of IKKb and IKKg inhibited TNFa-induced pS6K1(T389) in MCF-7 cells. MCF-7 cells were cotransfected with HA-
tagged S6K1 and either IKKb or IKKg siRNA and then treated with 20 ng/ml TNFa for 30 min.
(H) The IKKb inhibitors BAY 11-7082 (40 mM, 45 min pretreatment) and parthenolide (80 mM, 45 min pretreatment) and the mTOR inhibitor rapamycin
(50 nM, 3 h pretreatment) blocked TNFa-induced pS6K1(T389) in MCF-7 cells.
(I) Rapamycin abolished pS6K1(T389) in IKKb-transfectedMCF-7 cells but not in mTOR(S2035T)-transfectedMCF-7 cells. MCF-7 cells were cotrans-
fected with HA-tagged S6K1 and either IKKb or rapamycin-insensitive mTOR(S2035T) and then treated with 50nM rapamycin for 1 h.
(J) TNFa-induced mTOR activation was impaired in MCF-7 nIKKb stable transfectant.Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc. 443
Figure 3. Induction of mTOR Signaling by Inflammatory Cytokines
(A) TNFa, IL1b, and LPS induced pS6K1(T389) in MCF-7 cells and RAW264.7 mouse macrophages. Cells were serum-starved overnight and then
treated with 20 ng/ml TNFa, 20 ng/ml IL1b, and 10 ng/ml LPS for 30 min, respectively.
(B) siRNA-mediated knockdown of IKKb inhibited IL1b-induced pS6K1(T389) in MCF-7 cells. MCF-7 cells were cotransfected with HA-tagged S6K1
and IKKb siRNA and then treated with 20 ng/ml IL1b for 30 min.
(C) siRNA-mediated knockdown of Ikkb inhibited LPS-induced pS6K1(T389) in RAW264.7 mouse macrophage. RAW264.7 cells were cotransfected
with HA-tagged S6K1 and Ikkb siRNA and then treated with 10 ng/ml LPS for 30 min.
(D) pS6K1(T389) induction by TNFa (20 ng/ml) was similar to pS6K1(T389) induction by IGF1 (20 ng/ml), EGF (20 ng/ml), WNT3a (20 ng/ml), glucose
(15 mM), and amino acids.
(E) No significant effects on IGF1-, EGF-, or WNT3a-induced pS6K1(T389) in Ikkb/ MEFs.
(F) pS6K1(T389) induction by IGF1 (20 ng/ml), EGF (20 ng/ml), and WNT3a (20 ng/ml) was only slightly inhibited in IKKb-knockdown MCF-7 cells.IKKb Physically Interacts with TSC1
Our finding that IKKb activates themTORpathway promp-
ted us to investigate the mechanism by which IKKb acti-
vates mTOR. Since the TSC1/TSC2 complex and RHEB
are the upstream molecules responsible for the regulation
of mTOR activity, we investigated whether the regulation
of mTOR function by TNFa/IKKb signaling is through the
TSC complex. TNFa induced mTOR activation in Tsc1+/+
and Tsc2+/+ MEFs but not in Tsc1/ and Tsc2/ MEFs
in which the mTOR is constitutively activated (Figure 4A),
and this effect was recovered by re-expression of TSC1
and TSC2 in Tsc1/ and Tsc2/ MEFs, respectively
(Figure S3), indicating that TNFa-dependent mTOR acti-444 Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc.vation requires TSC1/2 complex. Increased pS6K1(T389)
levels as a result of transient expression of IKKb in
Tsc1+/+ but not in Tsc1/ MEFs (Figure 4B) further indi-
cated that TSC1 is involved in TNFa/IKKb-mediated
mTOR activation. Analysis of amino acid sequences re-
vealed that TSC1, but not TSC2 or RHEB, has a putative
IKKb phosphorylation site at Ser511 (Figure 4C). In
addition, cotransfection of TSC1 and IKKb showed that
IKKb caused the accumulation of a slow-migrating form
of TSC1 that was entirely eliminated by treatment with
calf intestinal alkaline phosphatase (Figure S4), indicat-
ing that the mobility shift was caused by phosphoryla-
tion of TSC1. Coimmunoprecipitation experiments further
showed that IKKb but not IKKa or IKKg physically associ-
ated with TSC1 (Figure S5). This interaction between IKKb
and TSC1 was also observed with endogenous IKKb and
TSC1 using specific antibodies to IKKb and TSC1
(Figure 4D), suggesting that IKKb physically associates
with TSC1. In vitro pull-down assay further suggested a di-
rect association between IKKb and TSC1 (Figure 4E).
Since IKKg was required for TNFa-induced mTOR activa-
tion (Figure 2G, right panel), we investigated whether IKKg
plays a role in the association between IKKb and TSC1.
IKKg-knockdownMCF-7 cells were used for a coimmuno-
precipitation assay and the results indicated that IKKg
was not necessary for the association between IKKb and
TSC1 (Figure S6). This result was consistent with the
fact that IKKg is only required for TNFa-induced mTOR
activation by IKKb (Figure 2G, right panel) whereas the as-
sociation between IKKb and TSC1 is direct (Figure 4E) and
independent of IKKg (Figure S6).
IKKb Phosphorylates TSC1 Predominantly at Ser487
and Ser511 In Vivo and In Vitro
Given the physical interaction between IKKb and TSC1
and the mobility shift induced by IKKb in TSC1, we exam-
ined whether TSC1 is a physiological substrate of IKKb. In
vitro kinase assays demonstrated that the TSC1 domain
301-600 was strongly phosphorylated by IKKb, whereas
other domains of TSC1 were not phosphorylated by
IKKb under the same conditions (Figure S7A, lanes 1-4).
Further analysis revealed that the phosphorylation sites
were located between residues 401-500 and 501-600 of
TSC1 (Figure S7B). The phosphorylation of TSC1was sim-
ilar in intensity to that of IkBa, a well-known substrate of
IKKb. Mass spectrometry analysis of GST-TSC1 frag-
ments showed that Ser487 and Ser511 were phosphory-
lated by IKKb (Figures S8A and S8B). Mutation of either
of these Ser residues to Ala (S487A or S511A) abolished
the phosphorylation of the TSC1 fragments by IKKb immu-
nocomplexes (Figure 4F) and purified IKKb kinase (data
not shown), suggesting that IKKb directly phosphorylates
TSC1 at both Ser487 (a nontraditional phosphorylation
site) andSer511 (an orthodox phosphorylation site) in vitro.
To assess whether these phosphorylations occur
in vivo, mass spectrometry analysis was performed. This
analysis showed that TSC1 Ser487 and Ser511 were
phosphorylated by IKKb in vivo (Figures S8C and S8D).
To investigate TSC1 phosphorylation by IKKb in vivo, we
raised rabbit polyclonal antibodies to TSC1 phosphory-
lated at Ser487 [pTSC1(S487)] or Ser511 [pTSC1(S511)]
in collaboration with Bethyl Laboratories and used these
antibodies to examine the phosphorylation status of
TSC1 in vivo. These antibodies specifically recognized
the phosphorylation of Ser487 and Ser511 by IKKb but
not by nIKKb and failed to detect any phosphorylation
when TSC1(SSAA) (in which both IKKb phosphorylation
sites were replaced with Ala to abolish the phosphoryla-
tion by IKKb) was cotransfected with IKKb (Figure 4G).
Consistent with our earlier finding that IKKb but not IKKa
interacted with TSC1 (Figure 4D), Ser487 and Ser511were phosphorylated by IKKb but not IKKa (Figure 4H).
Studies of the effect of TNFa on TSC1 phosphorylation
over time showed that pTSC1(S511) was induced by
TNFa between 10 and 30 min and then declined
(Figure 4I). Interestingly, pTSC1(S487) induced by TNFa
lasted longer than 1 h. The difference in the kinetics of
TNFa induction of pTSC1(S487) and pTSC1(S511) implied
that these two phosphorylations might be regulated by
distinct dephosphorylation mechanisms. Notably, TNFa-
induced pTSC1(S487) and pTSC1(S511) were abrogated
by the IKKb inhibitor BAY 11-7082 (Figure 4J) and by
IKKb siRNA (Figure S9A), suggesting that TNFa-induced
pTSC1(S487) and pTSC1(S511) are dependent on IKKb.
Furthermore, the anti-pTSC1(S511) antibody but not the
anti-TSC1(S487) antibody could be used for immunostain-
ing (Figure S9B and data not shown). After TNFa stimula-
tion, endogenous pTSC1(S511) was recognized by the an-
tibody; this phosphorylation signal was abrogated by the
IKKb inhibitor BAY 11-7082 and by the blocking phospho-
peptide but not by the control nonphosphopeptide
(Figure S9B). Taken together, our results showed that
TSC1 is phosphorylated by IKKb at Ser487 and Ser511
in vitro and in vivo and that IKKb is required for TNFa-
induced phosphorylation of TSC1.
Phosphorylation of TSC1 by IKKb Suppresses
TSC1 Function
On the basis of our observations that IKKb phosphory-
lates TSC1 and induces pS6K1(T389), we asked whether
IKKb phosphorylation leads to functional inactivation of
TSC1, thereby activating mTOR. To address this
issue, we generated six TSC1 mutants: TSC1(S487A),
TSC1(S511A), TSC1(SSAA), TSC1(S487D), TSC1(S511D),
and TSC1(SSDD). In TSC1(SSDD), both IKKb phosphory-
lation sites were replaced with Asp to mimic the phos-
phorylation of TSC1 by IKKb. We tested the effects of
these mutants on mTOR-dependent S6K1 phosphoryla-
tion at T389 in Tsc1-deficient MEFs. The pS6K1(T389)
levels in cells transfected with TSC1 Asp mutants were
higher than those in cells transfected with TSC1 Ala
mutants (Figure 5A). Moreover, TNFa could induce
pS6K1(T389) in TSC1(WT) but not in TSC1(SSAA)-
expressed Tsc1/ MEFs (Figure 5B). We further investi-
gated whether either one of the these two serines
(Ser487 and Ser511) may also be involved in TNFa-
induced mTOR activation. These results showed that mu-
tation of either one of these two sites only partially
inhibited TNFa-induced pS6K1(T389), suggesting that
both Ser487 and Ser511 were involved in regulation of
TNFa-induced mTOR activation (Figure 5C).
Next, we investigated the underlying mechanisms lead-
ing from TSC1 phosphorylation to mTOR activation. We
noticed that TSC1(SSDD) was consistently expressed at
a lower level than TSC1(WT) and TSC1(SSAA) when the
same amount of DNA was transfected. To ensure the
same level of TSC1 protein expression, the DNA amount
of TSC1(SSDD) used for transient transfection was greater
than the DNA amount of TSC1(WT) and TSC1(SSAA)Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc. 445
Figure 4. IKKb Phosphorylates TSC1 In Vivo and In Vitro
(A) TNFa induced mTOR activation in wild-type but not in Tsc1/ or Tsc2/ MEFs. Cells were serum-starved overnight and then treated with
20 ng/ml TNFa for 30 min.
(B) IKKb induced mTOR activation in Tsc1+/+ but not in Tsc1/ MEFs.
(C) TSC1 has a putative IKKb phosphorylation site at Ser511 (DS511LPGS). S, serine; T, threonine; c, hydrophobic amino acid; X, any amino acid.
(D) Endogenous TSC1 interacted with IKKb but not IKKa or IKKg. Lysates of MCF-7 cells were analyzed by reciprocal coimmunoprecipitation and
immunoblotting.
(E) TSC1 interacted directly with IKKb. In vitro transcribed TSC1 proteins were incubated with recombinant IKKb proteins and then pulled down by
antibody to IKKb. IVT, in vitro transcription and translation.446 Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc.
(Figures 5A and 5B). We tested whether phosphorylation
by IKKb affects TSC1 protein stability and thus contributes
to the inactivation of TSC1 function. Treatment with TNFa
increased the ubiquitination level of TSC1 and TSC2
(Figure S10A), and the ubiquitination level of TSC1(SSDD)
was higher than that of TSC1(SSAA) (Figure S10B). Treat-
ment with cycloheximide to inhibit protein synthesis fur-
ther revealed that the half-life of TSC1(SSDD) (10 h) was
shorter than that of TSC1(WT) (22 hr) or TSC1(SSAA)
(24 hr) (Figure 5D). Although the shorter half-life of the
phosphorylated TSC1 by IKKb reflects the fate of faster
degradation, it might not have a major role in TNFa-in-
duced mTOR activation, which occurs within 30 min
(Figure 1A).
Since TSC1 stabilizes TSC2 by preventing the associa-
tion between TSC2 and HERC1 ubiquitin ligase, enhances
TSC2 GAP function, and further inhibits mTOR activity
(Chong-Kopera et al., 2006), we investigated whether
phosphorylation of TSC1 by IKKb inhibits TSC1/TSC2
complex formation. Indeed, TNFa treatment, which in-
duced IKKb to phosphorylate TSC1, interfered with TSC
complex formation (Figure 5E). Consistent with this find-
ing, TSC1(SSDD) had a weaker interaction with TSC2
than did TSC1(WT) or TSC1(SSAA) (Figure S10C). Taken
together, these results suggested that the IKKb-depen-
dent phosphorylation of TSC1 enhances dissociation of
TSC1/TSC2 complex, which in turn induces mTOR
activation.
Recently, the membrane-associated TSC1/TSC2 com-
plex has been recognized to be biologically active and
able to impede RHEB function (Potter et al., 2002). We
therefore examined whether phosphorylation by IKKb af-
fects the membrane localization of TSC1 and TSC2. The
membrane-bound TSC1 did not change its subcellular lo-
calization in response to TNFa (Figure 5F). Consistently,
both TSC1(SSAA) and TSC1(SSDD) mutants localized at
the membrane fractions (Figure S10D). Interestingly, we
observed a small fraction of the membrane-associated
TSC2 migrated to the cytosol after TNFa treatment
(Figure 5F). This may be due to the fact that phosphoryla-
tion of TSC1 by IKKb inhibits the association of TSC1 with
TSC2 and thereby promotes a change in the subcellular
localization of TSC2. Collectively, our results indicated
that phosphorylation of TSC1 by IKKb interferes with the
association of TSC1 with TSC2, which alters TSC2 mem-
brane localization and activates the mTOR pathway.
Repression of TSC1 Promotes Tumor Angiogenesis
We next asked whether phosphorylation by IKKb also
affects the tumor suppressor function of TSC1. In vivotumorigenesis assays revealed that the expression of
both TSC1(WT) and TSC1(SSAA) profoundly antagonized
tumorigenesis of 4T1 cells (82% reduction in tumor vol-
ume compared with the vector control), whereas
TSC1(SSDD) had little effect (Figure 6A). In comparison
with TSC1(WT), the stronger tumor suppression effect of
TSC1(SSAA) could be detected in the first three weeks
(Figure 6A and Table S1). To investigate whether activa-
tion of the mTOR pathway plays a role in IKKb-induced
tumorigenesis, we treated mice bearing 4T1-IKKb, 4T1-
nIKKb, 4T1-TSC1(SSDD), and 4T1-TSC1(SSAA) tumors
with the mTOR inhibitor rapamycin. Rapamycin inhibited
4T1-IKKb-mediated (Figure 6B) and 4T1-TSC1(SSDD)-
mediated tumor progression (Figure 6C). Furthermore,
TSC1(SSAA), which suppressed mTOR activity (Figures
5A and 5B), strongly inhibited IKKb-mediated tumor pro-
gression (Figure 6D), while TSC1(WT), which could still
respond to TNFa/IKKb-induced phosphorylation and
inactivation, only partially interfered with IKKb-induced
tumorigenesis, indicating that activation of the TSC/
mTOR pathway is required for IKKb-mediated tumor
development.
Since loss of Tsc1 leads to upregulation of Vegf expres-
sion, which is dependent on the mTOR pathway, and this
event contributes to the vascular nature of TSC lesions
(El-Hashemite et al., 2003), we assessed themean density
of blood vessels from 4T1 tumors to elucidate whether
TSC1(SSDD) loses antiangiogenic activity and therefore
lacks tumor suppressor function. Indeed, the mean blood
vessel density in 4T1-TSC1(SSDD) tumors was signifi-
cantly higher than the mean blood vessel density in
4T1-TSC1(WT) and 4T1-TSC1(SSAA) tumors (Figure 6E),
suggesting that phosphorylation by IKKb impairs the anti-
angiogenic function of TSC1. A similar result was found in
mice bearing 4T1 tumors injected intratumorally with var-
ious TSC1 constructs complexed with DOTAP:Chol lipo-
some (Figure S11A). The notion that IKKb impairs the anti-
angiogenic function of TSC1was further supported by two
in vitro angiogenesis assays, the human umbilical vein en-
dothelial cell (HUVEC) tube formation and migration as-
says: TSC1(SSAA) stable transfectants had a stronger
ability than did TSC1(SSDD) transfectants to inhibit HU-
VEC tube formation and migration (Figures 6F and
Figure S11B).
To further address how phosphorylated TSC1 loses its
antiangiogenic ability to suppress VEGF, we measured
VEGF secretion from stable transfectants. TSC1(SSAA)
transfectants, but not TSC1(SSDD) transfectants, in-
hibited VEGF secretion (Figure 6G). Similar results were
found in MDA-MB-453 cells transiently transfected with(F) The IKKb phosphorylation sites Ser487 and Ser511 were identified by in vitro kinase assays in which IKKb and nIKKb immunocomplexes from
HEK293 cells were incubated with the indicated GST-TSC1 fusion proteins. WT, wild-type.
(G) Characterization of antibodies to pTSC1(S487) and pTSC1(S511). Myc-tagged TSC1(wild-type) and TSC1(SSAA) were cotransfected with Flag-
tagged IKKb or nIKKb, immunoprecipitated, and analyzed with antibodies to pTSC1(S487) and pTSC1(S511).
(H) IKKa did not phosphorylate TSC1 at Ser487 or Ser511. Myc-tagged TSC1(wild-type) was cotransfected with Flag-tagged IKKa, IKKb, or nIKKb,
immunoprecipitated, and analyzed with antibodies to pTSC1(S487) and pTSC1(S511).
(I) TNFa induced phosphorylation of endogenous TSC1 at Ser487 and Ser511 in MCF-7 cells.
(J) The IKKb inhibitor BAY 11-7082 inhibited TNFa-induced phosphorylation of TSC1 at Ser487 and Ser511.Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc. 447
Figure 5. IKKb Phosphorylation Suppresses TSC1 Function
(A) pS6K(T389) levels were lower in cells transfected with TSC1 Ala mutants than in cells transfected with TSC1 Asp mutants. HA-tagged S6K1 was
transiently transfected into Tsc1-deficient MEFs with wild-type TSC1 or the indicated mutants of TSC1, and expression was analyzed by antibody to
pS6K(T389) after 16 h of serum starvation. To ensure the same level of TSC1 protein expression, the DNA amount of TSC1 Asp mutants used for
transfection was greater than the DNA amount of TSC1 wild-type and Ala mutants.
(B) Induction of pS6K1(T389) by TNFa was repressed in TSC1(SSAA)-transfected Tsc1/ MEFs.
(C) TSC1(SSAA) strongly suppressed TNFa-induced pS6K1(T389), while TSC1(S487A) and TSC1(S511A) only had partial effects.
(D) The TSC1(SSDD) mutant was less stable than TSC1(WT) or TSC1(SSAA). The stability of wild-type and mutant TSC1 was determined by cyclo-
heximide (100 mg/ml) treatment.
(E) TNFa disrupted the interaction between TSC1 and TSC2. MCF-7 cells were serum-starved overnight and then treated with either 20 ng/ml TNFa,
20 ng/ml IGF1, or 20 ng/ml EGF for 30 min, immunoprecipitated by antibody to TSC2, and analyzed with antibody to TSC1.448 Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc.
various TSC1 mutants (Figure S11C). Depletion of VEGF
by VEGF-specific antibody repressed the HUVEC tube
formation ability of TSC1(SSDD) to a level similar to that
for the HUVEC tube formation ability of TSC1(SSAA)
(Figure 6H). Moreover, the cell growth and VEGF secretion
induced by TNFa were lower in TSC1(SSAA) stable trans-
fectant than in TSC1(WT) stable transfectants (Figures
S11D and S11E), and the TSC1(WT)- and TSC1(SSAA)-
mediated suppression of VEGF expression and HUVEC
tube formation were diminished after transfection of con-
stitutively active S6K1(E389D3E) (Figures 6F and 6G ver-
sus Figures S11F and S11G). In addition, rapamycin
strongly suppressed VEGF expression induced by IKKb
but had much less effect on VEGF expression induced
by a rapamycin-insensitivemTOR (S2035T)mutant (Figure
S11H). Taken together, our results suggest that TSC1
exerts an antiangiogenic effect through suppression of
VEGF expression and also suggest that phosphorylation
of TSC1 by IKKb activates mTOR and then de-represses
VEGF expression, impairing the antiangiogenic function
of TSC1.
Clinical Relevance of pTSC1(S511)
in Human Tumor Tissues
To further examine whether the aforementioned conclu-
sions could be supported in human primary tumors,
we studied the expression of pIKKb(S181) (activated
IKKb) and pTSC1(S511) in 115 human primary breast
tumor specimens by immunohistochemical staining.
pIKKb(S181) was strongly correlated with the expression
of TNFa and pIkBa(S32/S36) (Figures S12A and S12B),
suggesting that pIKKb(S181) can be used to stand for
both TNFa-stimulated signaling and IKKb kinase activity.
Moreover, pTSC1(S511) was detected in 29 (69%) of the
42 specimens with high pIKKb(S181) expression but in
only 22 (30%) of the 73 specimens with low pIKKb(S181)
expression, indicating that pIKKb(S181) expression was
associated with high levels of pTSC1(S511) (p < 0.001;
Figures 7A and 7B). Consistent with this finding,
pTSC1(S511) expression was also strongly associated
with pS6K1(T389) and VEGF expression (p < 0.001; Fig-
ures 7A and 7B). We also performed kinase assays and
immunoblotting using 10 freshly prepared human breast
tumor lysates to validate the relationships between
IKKb kinase activity, pTSC1(S511) expression, and
pS6K1(T389) expression. Consistent with the findings
on immunohistochemical staining, IKKb kinase activity
was significantly associated with pTSC1(S511) and
pS6K1(T389) by immunoblotting [p < 0.01 for IKKb kinase
activity and pTSC1(S511); p < 0.05 for IKKb kinase activity
and pS6K1(T389); p < 0.01 for pTSC1(S511) and
pS6K1(T389); Figures 7C and 7D]. To investigate whether
the association between pTSC1(S511) and pIKKb(S181)also occurs in other tumor types, human tumor tis-
sue arrays were examined. The results demonstrated
that pTSC1(S511) expression was associated with
pIKKb(S181) not only in breast cancer but also in many
other kinds of cancers, including colon and liver cancers
(Figure S12C and Table S2). In addition, the percentage
of pTSC1(S511)-positive normal tissues (24.8%) was sig-
nificantly lower than the percentage of pTSC1(S511)-
positive tumor tissues (69.7%) (p < 0.001; Figure S12C
and Tables S2 and S3), suggesting that phosphorylation
of TSC1 by IKKb is pathologically relevant in multiple hu-
man tumors. We next analyzed the expression of
pTSC1(S511) and pS6K1(T389) in breast tumor tissues
and correlated the findings with patient survival data.
The Kaplan-Meier overall survival curves showed that
high pTSC1(S511) and pS6K1(T389) levels were associ-
ated with poor survival. Moreover, the combination of
pTSC1(S511) and pS6K1(T389) was a better predictor of
survival than was either factor alone (p < 0.01 versus p <
0.05) (Figure 7E). Taken together, the tumor immunohisto-
chemical staining data further strengthened the notion
that phosphorylation of TSC1 by IKKb promotes S6K1 ac-
tivation and VEGF production and is associated with poor
clinical outcome of breast cancer patients.
DISCUSSION
The link between inflammation and tumor progression has
been suspected for about two hundred years, and accu-
mulating evidence supports a tumor-promoting role of
inflammation, brilliantly described by Balkwill and Manto-
vani as follows: ‘‘If genetic damage is the ‘match that lights
the fire’ of cancer, some types of inflammationmayprovide
the ‘fuel that feeds the flames’’’ (Balkwill and Mantovani,
2001). The proinflammatory cytokines and chemokines
produced in the tumor microenvironment, such as TNFa,
IL-1, IL-6, and IL-8, enhance cell proliferation, cell survival,
cell migration, and tumor angiogenesis, thereby promot-
ing tumor development (Karin andGreten, 2005). Although
accumulating evidence suggests that angiogenesis
plays a role in inflammation-mediated tumorigenesis, the
detailed mechanisms by which inflammation facilitates
tumor development remain to be further investigated.
Activation of the mTOR Pathway by TNFa
Dysregulation of TNFa signaling pathway contributes to
the development of human cancers due to enhanced
IKK activity and constitutive NF-kB activation. Here, we
showed that TNFa also stimulates mTOR signaling, which
is known to upregulate protein translation including VEGF,
through phosphorylation and inactivation of TSC1 by IKKb
in breast cancers. This regulation may be relevant in both
the epithelial tumors and hematological malignancies, and(F) TSC1 remained membrane bound in response to TNFa, whereas some portion of TSC2 migrated to the cytosol. The membrane and cytosolic
fractions of serum-starved MCF7 cells that were stimulated with 20ng/ml TNFa for 30 min were analyzed by immunoblotting with antibodies to
TSC1 and TSC2. E-CADHERIN was used as the membrane marker, and GAPDH was used as the cytosolic marker. M, membrane fraction; C, cyto-
solic fraction. The plots represent the mean of three independent experiments and error bars represent SD.Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc. 449
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contribute to not only tumor progression but also tumor
metastasis as VEGF-regulated angiogenesis is a key fac-
tor for metastasis. On the basis of our findings, we pro-
pose a model in which elevated TNFa from macrophages
and tumor cells upregulates the mTOR pathway through
inactivation of TSC1 by IKKb, leading to increasing VEGF
expression and promotion of tumor angiogenesis (Fig-
ure 7F). It is worthwhile to mention that TNFa stimulates
AKT activation dependent upon cell types (Delhase
et al., 2000; Ghosh et al., 2006; Ozes et al., 2001). Thus,
it may be possible that TNFa could activate both IKKb
and AKT to inactivate TSC1 and TSC2, respectively, and
then results in mTOR activation in certain cell types. Inter-
estingly, a recently published study by T. Hunter and col-
leagues demonstrated the attenuation of NF-kB activation
due to constitutive mTOR activation in TSC-derived tu-
mors, which might explain why tuberous sclerosis are
weakly malignant (Ghosh et al., 2006). The mTOR activity
is inducible by cytokines and the level is modest com-
pared with the constitutively activated mTOR activity in
the Tsc null cells (Figure 4A). Since TNFa-induced NF-kB
activation is regulated normally in the cells with functional
TSC1/TSC2, we speculate that the impairment of NF-kB
activation might only occur in the tumors with deficient
or mutated TSC1/TSC2 in which the mTOR is constitu-
tively and highly activated, but not in tumors with normal
TSC function. Integrating these findings may provide
a new view on the therapeutic intervention for inflamma-
tion-mediated cancers by using IKK inhibitors or combin-
ing NF-kB inhibitors and rapamycin.
TNFa-activated IKK Complex and Individual
Functionality of IKKb
The requirement of IKK complex for activation of NF-kB
has been studied for many years. Although dogma holds
that IKK kinase is an IkB kinase that is responsible for
the phosphorylation of IkBs, growing evidence suggests
that IKKa and IKKb also play other roles in regulating phys-
iological reactions. For instance, IKKa shuttles from cyto-
plasm to nucleus and phosphorylates HISTONE H3 and
CBP (Anest et al., 2003; Huang et al., 2007; Yamamotoet al., 2003), and IKKb can phosphorylate and modulate
the functions of several cytosol proteins, including b-CAT-
ENIN (Lamberti et al., 2001), SRC-3 (Wu et al., 2002),
FOXO3a (Hu et al., 2004), CYLD (Lee et al., 2004), and
DOK1 (Reiley et al., 2005). Curiously, our study of the inter-
action between TSC1 and the IKK complex revealed that
only IKKb, not IKKa, associates with TSC1, suggesting
that TSC1-associated IKKb might be a free form of IKKb.
However, TSC1 phosphorylation and S6K1 phosphoryla-
tion were increased after TNFa stimulation, and knock-
down of IKKg, a component in the IKK complex known
to be required for activation of IKKb, abolished TNFa-in-
duced mTOR activation. These findings suggested that
the complete IKK complex is required for TNFa-induced
TSC1 phosphorylation and mTOR activation. Together
with the existing knowledge and our results that IKKb
(but not IKKa and IKKg) associates with TSC1, and the
basal level of pS6K1(T389) is reduced in both IKKb-knock-
down and IKKb inhibitor-treated cells (Figures 2G and 2H)
but not IKKg-knockdown cells (Figure 2G), an interesting
model emerges: in response to extracellular cytokines
such as TNFa, the IKK complex is activated and then
phosphorylates IkB inhibitors. However, some portions
of activated IKK kinases might dissociate from this com-
plex and administer branched-out functions. IKKa moves
into the nucleus and phosphorylates its nuclear substrates
to regulate gene transcription; IKKb, which could be free
from the IKK complex, stays in the cytosol and phosphor-
ylates its cytosolic substrates, such as TSC1, to activate
the mTOR pathway and promote protein translation.
Thus, IKK complex may regulate the expression of certain
genes, such as VEGF, through both transcriptional and
translational processes.
Inflammation-Mediated Tumor Angiogenesis
The inflammatory microenvironment in and around tumors
contains several types of inflammatory cells, especially tu-
mor-associated macrophages (TAMs), that secrete proin-
flammatory cytokines and chemokines—including TNFa,
IL-1, IL-6, and IL-8—to enhance cell proliferation, cell sur-
vival, and angiogenesis and thereby promote tumorFigure 6. Phosphorylation of TSC1 by IKKb Impairs the Antiangiogenic Function of TSC1
(A) TSC1(WT) and TSC1(SSAA) profoundly inhibited tumorigenesis, whereas TSC1(SSDD) had little effect. Error bars represent SD (n = 5).
(B-C) The mTOR inhibitor rapamycin inhibited IKKb-mediated and TSC1(SSDD)-mediated tumorigenesis. Rapamycin (1.5 mg/ kg) was injected into
tumor-bearing BALB/c mice three times per week for 2 weeks and then tumor volumes were determined. Symbols are as follows: arrowheads, dates
of rapamycin injection; asterisk, date of last treatment. Error bars represent SD (n = 5).
(D) TSC1(SSAA) had a better suppression effect on IKKb-mediated tumorigenesis than did TSC1(WT). 4T1 mouse mammary tumor cells were co-
transfected with various GFP-tagged TSC1 constructs and (n)IKKb, and GFP-positive cells were sorted by flow cytometry. The sorted cells were
then injected into the mammary fat pads of BALB/c mice for in vivo tumorigenesis assays. Error bars represent SD (n = 5).
(E) 4T1-TSC1(SSDD) tumor had greater blood vessel density than did 4T1-TSC1(WT) and 4T1-TSC1(SSAA) tumors in vivo. Frozen tumor sections
were fixed, stained with CD31 (red) antibody to permit determination of the number of blood vessels, and counterstained with TOPRO-3 dye
(blue) to permit visualization of nuclei. Error bars represent SD (n = 3).
(F) 453-TSC1(SSDD) stable transfectant had a weaker ability to repress HUVEC tube formation than did 453-TSC1(WT) and 453-TSC1(SSAA) stable
transfectants. Tube formation assays were performed by culturing HUVECs with the supernatants of various TSC1 stable transfectants. Error bars
represent SD (n = 3).
(G) 453-TSC1(SSDD) stable transfectant secreted more VEGF than did 453-TSC1(WT) and 453-TSC1(SSAA) stable transfectants. VEGF secretion
from various TSC1 stable transfectants was quantified by ELISA. Error bars represent SD (n = 3).
(H) Depletion of VEGF by antibody to VEGF (a-VEGF) repressed HUVEC tube formation in various TSC1 stable transfectants. Error bars represent SD
(n = 3).Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc. 451
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progression. TAMs, derived from circulating monocytic
precursors, are widespread in human breast cancers
and have been suggested to play a vital role in tumor an-
giogenesis (Bingle et al., 2002). It has been suggested that
the proinflammatory cytokine TNFa induces tumor cells to
secrete VEGF through NF-kB-mediated transcriptions of
VEGF and hypoxia-inducible factor-1b. Recently, TBK1,
an IKK kinase involved in both NF-kB and IRF3 signaling
(Fitzgerald et al., 2003), was identified as a proangiogenic
trigger by high-throughput functional genomic screen (Ko-
rherr et al., 2006), implying that inflammatory signaling
pathways play important roles in promoting tumor angio-
genesis. Our finding that TNFamediates tumor angiogen-
esis through dysregulated mTOR signaling caused by
suppression of TSC1 by IKKb reveals a novel mecha-
nism of inflammation-mediated tumor angiogenesis.
Collectively, these findings suggest that inflammation-
mediated tumor angiogenesis may occur through both
transcriptional (NF-kB and IRF3) and translational controls
(mTOR) by multiple distinct inflammation-associated
kinases, including IKKb and TBK1.
The identification of TSC1 as a downstream effector of
IKKb links the TNFa and mTOR signaling pathways and
provides an important new starting point for uncovering
the molecular basis of TNFa-mediated human tumor an-
giogenesis and identifying potential targets for antiangio-
genic therapy. Further investigations of the IKKb/TSC1/
mTOR signaling pathway may identify new molecules in-
volved in regulating TNFa-induced pathological disorders.
Preventing the phosphorylation of TSC1 may have impor-
tant clinical implications for the treatment or prevention of
cancer.
EXPERIMENTAL PROCEDURES
Supplemental Experimental Procedures are provided in the Supple-
mental Data.
Cell Culture, Stable Transfectants, and Transfection
MCF-7, MDA-MB-453, HBL-100, RAW264.7, and HEK293 cells and
Ikkb/, Tsc1+/+, Tsc1/, Tsc2+/+p53/, and Tsc2/p53/ MEFs
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F12
medium supplemented with 10% fetal bovine serum. MCF-10A was
cultured in DMEM/F12 medium supplemented with 5% horse serum,
10 mg/ml insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin, and
500 ng/ml hydrocortisone. IKKb and TSC1 stable transfectants wereselected by blasticidin S and G418, respectively. For transient trans-
fection, cells were transfected with DNA by either SN liposome (Zou
et al., 2002), lipofectamine with plus reagent, or electroporation using
a Nucleofector 1 device (Amaxa) with electroporation buffer (137 mM
NaCl, 5mMKCl, 0.7mMNa2HPO4, 6mMglucose, and 20mMHEPES,
pH 7.0). To investigate the effects of agonists on pS6K1(T389), the
transfected cells were serum-starved overnight and extracted directly
or after stimulation with TNFa, IL-1b, LPS, IGF1, EGF,WNT3a, TGF-b1,
glucose, or amino acids for 30 min.
Subcellular Fractionation
Membrane-bound and cytosolic TSC1 and TSC2 proteins were sepa-
rated by hypotonic buffer as previously described (Cai et al., 2006).
Mouse Model for Tumorigenesis and Angiogenesis Studies
The tumorigenesis assays were performed using an orthotopic breast
cancer mouse model as previously described (Chang et al., 1997). The
mousemammary tumor cell line 4T1was transfectedwith variousGFP-
tagged TSC1 constructs, and the GFP-positive cells were sorted by
flow cytometry. Cells (1 3 105) were injected into the mammary fat
pads of BALB/c mice (The Jackson Laboratory; 5 mice per group),
and the volumes of the resulting tumors were measured twice a week
after tumorswere detected by an IVIS imagining system (Xenogen). An-
giogenesiswas examinedbyCD31 immunostaining. The datawere an-
alyzed using Student’s t test. For intratumoral injection, the 4T1 cells
were inoculated in the mammary fat pads of the mice. When tumor
size reached about 7mm3, various TSC1 constructs (50 mg) complexed
withDOTAP:Chol liposome (50ml) were injected into tumors three times
per week. After 1 week of treatment, mice were sacrificed, and tumor
samples were examined for angiogenesis by CD31 immunostaining.
Immunohistochemical Staining and Human Breast
Tumor Samples
Immunohistochemical staining was performed as previously de-
scribed (Deng et al., 2002; Hu et al., 2004). Human HistoArrays
IMH-365 (multiple cancerous tissues), IMH-301 (normal organs), and
IMH-337 (normal tissues) were purchased from Imgenex. Human tis-
sue specimens were incubated with antibodies to pTSC1(S511),
pS6K1(T389), pIKKb(S181), VEGF, or TNFa and biotin-conjugated
secondary antibody and then incubated with avidin-biotin-peroxidase
complex, and visualization was performed with amino-ethylcarbazole
chromogen. The human breast tumor samples for IKKb kinase assay
and Western blotting were received from the breast tumor bank of
The University of Texas M. D. Anderson Cancer Center. Fisher’s exact
test and Spearman rank correlation were used for statistical analysis;
p < 0.05 was considered statistically significant. According to
histologic scoring, the intensity of staining was ranked into four groups:
high (score 3), medium (score 2), low (score 1), and negative (score 0).
The immunoreactivities for pTSC1(S511), pS6K1(T389), pIKKb(S181),
VEGF, and TNFa were semiquantitatively scored using a well-
established immunoreactivity score system in which immunoreactivityFigure 7. Clinical Association between pTSC1(S511) Expression; pIKKb(S181), pS6K1(T389), and VEGF Expression, and Survival
of Breast Cancer Patients
(A) pTSC1(S511) level was associated with pIKKb(S181), pS6K1(T389), or VEGF expression in 115 primary human breast cancer specimens. Shown
are two representative specimens.
(B) Left panel shows percentages of specimens with low () or high (+) pIKKb(S181) expression in which pTSC1(S511) was or was not observed. Mid-
dle and right panels show the percentages of specimens with low () or high (+) pTSC1(S511) expression in which pS6K1(T389) or VEGF expression
was or was not observed.
(C) IKKb activity was associated with pTSC1(S511) and pS6K1(T389) expression in 10 freshly prepared human breast tumor lysates. IKKb activity was
determined by in vitro kinase assay, and the expression levels of pTSC1(S511) and pS6K1(T389) were determined by immunoblotting.
(D) Correlation analyses between IKKb kinase activity and pTSC1(S511) and pS6K1(T389) expression levels were performed by Spearman rank
correlation.
(E) The Kaplan-Meier overall survival curves indicated that pTSC1(S511) and pS6K1(T389), alone and together, are associated with a reduction of
overall survival in breast cancer patients.
(F) A model in which phosphorylation of TSC1 by IKKb activates the mTOR pathway and thereby induces tumor angiogenesis.Cell 130, 440–455, August 10, 2007 ª2007 Elsevier Inc. 453
score was generated by incorporating both the percentage of positive
tumor cells and the intensity of staining (Camp et al., 1999). An immu-
noreactivity score less than 150 was considered negative (); an
immunoreactivity score greater than 150 was considered positive (+).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, three tables, and twelve figures and can
be found with this article online at http://www.cell.com/cgi/content/
full/130/3/440/DC1/.
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